Thymoma and Thymic Carcinoma Clinical Trial
Official title:
A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma
This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.
The previous trials have showed that radiotherapy was significantly associated with prolonged OS and chemotherapy is playing an increasing role in treatment of patients with thymoma or thymic carcinoma.However,whether patients with thymoma or thymic carcinoma could benefit from adjuvant radiochemotherapy after incomplete resection remains controversial. The purpose of this study is to investigate whether adjuvant radiochemotherapy after incomplete resection can improve survival for thymoma or thymic carcinoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00003283 -
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
|
Phase 2 | |
| Completed |
NCT00372840 -
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
|
N/A | |
| Completed |
NCT00024076 -
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
|
Phase 2 | |
| Completed |
NCT02636556 -
Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
|
N/A | |
| Completed |
NCT02049047 -
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT04554524 -
Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma
|
Phase 4 | |
| Active, not recruiting |
NCT03663764 -
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
|
Phase 2 | |
| Recruiting |
NCT06301945 -
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
|